Less Invasive Surfactant Administration: A Review of Current Evidence of Clinical Outcomes With Beractant

Cureus. 2022 Oct 12;14(10):e30223. doi: 10.7759/cureus.30223. eCollection 2022 Oct.

Abstract

Evidence supporting clinical recommendations or approval for less invasive surfactant administration (LISA) has primarily examined heterogeneous or small-volume (e.g., 1.25-2.5 mL/kg) animal-derived surfactant regimens. To address the evidence gap for larger-volume (e.g., 4-5 mL/kg) animal-derived surfactants, the aim of this review was to evaluate and summarize LISA literature for widely used larger-volume beractant. Surfactant treatment and the LISA technique were initially summarized. The available literature on beractant with LISA was thoroughly assessed and reviewed, including a recent systematic analysis, studies from regions where access or preferences may influence reliance on larger-volume surfactants, and investigations of short- and long-term outcomes. The available literature indicated improved short-term outcomes, including less need for mechanical ventilation, death, or bronchopulmonary dysplasia, and no negative long-term developmental outcomes when beractant was administered via LISA compared with older, more invasive techniques. The rates of short-term outcomes were similar to those previously observed in examinations of LISA with small-volume surfactants, including in populations reflecting very preterm infants. As uptake of LISA is expected to increase, future research directions for larger-volume surfactants include cost-effectiveness evaluations and robust examinations of repeat dosing and surfactant reflux to further inform clinical practice. This review provides a detailed assessment of the literature describing surfactant and LISA, with a focus on studies of beractant. Collectively, the available evidence supports the use of beractant with LISA based both on short-term and long-term outcomes relative to more invasive techniques and comparability of outcomes with small-volume surfactants and may be valuable in guiding clinical decision-making.

Keywords: bronchopulmonary dysplasia; insure; less invasive surfactant administration (lisa); mechanical ventilation; preterm infants; respiratory distress syndrome; surfactant deficiency.

Publication types

  • Review

Grants and funding

This work was supported by AbbVie, Inc., North Chicago, IL. AbbVie was involved in the study design; data collection, analysis, and interpretation; report writing, and the decision to submit the article for publication.